Patents by Inventor G. Edward Cartier
G. Edward Cartier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6958323Abstract: The present invention relates to the use of ?-conotoxin peptides having the general formula Xaa1-Xaa2-Cys-Cys-Xaa3-Xaa4-Pro-Xaa5-Cys-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11-Xaa12-Cys (SEQ ID NO:1) for treating disorders regulated at neuronal nicotinic acetylcholine receptors. Such disorders include, but are not limited to, cardiovascular disorders, gastric motility disorders, urinary incontinence, nicotine addiction, mood disorders (such as bipolar disorder, unipolar depression, dysthymia and seasonal effective disorder) and small cell lung carcinoma, as well as the localization of small cell lung carcinoma. In this formula, Xaa1 is des-Xaa1, Tyr, mono-iodo-Tyr or di-iodo-Tyr, Xaa2 is any amino acid, Xaa3 is any amino acid, Xaa4 is any amino acid, Xaa5 is any amino acid; Xaa6 is any amino acid, Xaa7 is any amino acid, Xaa8 is any amino acid, Xaa9 is des-Xaa9 or any amino acid, Xaa10 is des-Xaa10 or any amino acid, Xaa11 is des-Xaa11 or any amino acid and Xaa2 is des-Xaa12 or any amino acid.Type: GrantFiled: July 3, 2001Date of Patent: October 25, 2005Assignees: University of Utah Research Fnd., Cognetix, Inc.Inventors: Baldomero M. Olivera, J. Michael McIntosh, Doju Yoshikami, G. Edward Cartier, Siqin Luo
-
Publication number: 20040192886Abstract: The present invention is to &mgr;-conopeptides, derivatives or pharmaceutically acceptable salts thereof. The present invention is further directed to the use of this peptide, derivatives thereof and pharmaceutically acceptable salts thereof for the treatment of disorders associated with voltage-gated sodium channels. Thus, the &mgr;-conopeptides or derivatives are useful as neuromuscular blocking agents, local anesthetic agents, analgesic agents and neuroprotective agents. The &mgr;-conopeptides are also useful for treating neuromuscular disorders. The invention is further directed to nucleic acid sequences encoding the &mgr;-conopeptides and encoding propeptides, as well as the propeptides.Type: ApplicationFiled: April 21, 2004Publication date: September 30, 2004Applicants: The University of Utah Research Foundation, Cognetix, Inc.Inventors: Baldomero M. Olivera, J. Michael McIntosh, James E. Garrett, Maren Watkins, Lourdes J. Cruz, Ki-Joon Shon, Richard B. Jacobsen, Robert M. Jones, G. Edward Cartier, Gregory S. Shen, John D. Wagstaff
-
Publication number: 20040192610Abstract: The present invention relates to the use of &agr;-conotoxin peptides having the general formula Xaa1-Xaa2-Cys-Cys-Xaa3-Xaa4-Pro-Xaa5-Cys-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11-Xaa12-Cys (SEQ ID NO:1) for treating disorders regulated at neuronal nicotinic acetylcholine receptors. Such disorders include, but are not limited to, cardiovascular disorders, gastric motility disorders, urinary incontinence, nicotine addiction, mood disorders (such as bipolar disorder, unipolar depression, dysthymia and seasonal effective disorder) and small cell lung carcinoma, as well as the localization of small cell lung carcinoma. In this formula, Xaa1 is des-Xaa1, Tyr, mono-iodo-Tyr or di-iodo-Tyr, Xaa2 is any amino acid, Xaa3 is any amino acid, Xaa4 is any amino acid, Xaa5 is any amino acid; Xaa6 is any amino acid, Xaa7 is any amino acid, Xaa8 is any amino acid, Xaa9 is des-Xaa9 or any amino acid, Xaa10 is des-Xaa10 or any amino acid, Xaa11 is des-Xaa11 or any amino acid and Xaa12 is des-Xaa12 or any amino acid.Type: ApplicationFiled: April 20, 2004Publication date: September 30, 2004Applicants: The University of Utah Research Foundation, Cognetix, Inc.Inventors: Baldomero M. Olivera, J. Michael McIntosh, Doju Yoshikami, G. Edward Cartier, Sigin Luo
-
Patent number: 6762165Abstract: The invention relates to relatively short peptides (termed O-Superfamily conotoxins herein), about 20-40 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds.Type: GrantFiled: December 28, 2000Date of Patent: July 13, 2004Assignees: University of Utah Research Foundation, Cognetix, Inc.Inventors: Baldomero M. Olivera, G. Edward Cartier, Maren Watkins, David R. Hillyard, J. Michael McIntosh, Richard T. Layer, Robert M. Jones
-
Publication number: 20040132663Abstract: The invention relates to &ohgr;-conopeptides, derivatives or pharmaceutically acceptable salts thereof, and uses thereof, including the treatment of neurologic and psychiatric disorders, such as anticonvulsant agents, as neuroprotective agents, as cardiovascular agents or for the management of pain. The invention further relates to nucleic acid sequences encoding the conopeptides and encoding propeptides, as well as the propeptides.Type: ApplicationFiled: January 29, 2004Publication date: July 8, 2004Applicants: University of Utah Research Foundation, Cognetix, Inc.Inventors: Baldomero M. Olivera, J. Michael McIntosh, Maren Watkins, James E. Garrett, Ki-Joon Shon, Richard B. Jacobsen, Robert M. Jones, G. Edward Cartier
-
Patent number: 6727226Abstract: The present invention is to &mgr;-conopeptides, derivatives or pharmaceutically acceptable salts thereof. The present invention is further directed to the use of this peptide, derivatives thereof and pharmaceutically acceptable salts thereof for the treatment of disorders associated with voltage-gated sodium channels. Thus, the &mgr;-conopeptides or derivatives are useful as neuromuscular blocking agents, local anesthetic agents, analgesic agents and neuroprotective agents. The &mgr;-conopeptides are also useful for treating neuromuscular disorders. The invention is further directed to nucleic acid sequences encoding the &mgr;-conopeptides and encoding propeptides, as well as the propeptides.Type: GrantFiled: July 23, 2001Date of Patent: April 27, 2004Assignees: University of Utah Research Foundation, Cognetix, Inc.Inventors: Baldomero M. Olivera, J. Michael McIntosh, James E. Garrett, Lourdes J. Cruz, Robert M. Jones, G. Edward Cartier, John D. Wagstaff
-
Publication number: 20030119731Abstract: The invention relates to &ohgr;-conopeptides, derivatives or pharmaceutically acceptable salts thereof, and uses thereof, including the treatment of neurologic and psychiatric disorders, such as anticonvulsant agents, as neuroprotective agents, as cardiovascular agents or for the management of pain. The invention further relates to nucleic acid sequences encoding the conopeptides and encoding propeptides, as well as the propeptides.Type: ApplicationFiled: July 23, 2001Publication date: June 26, 2003Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventors: Baldomero M. Olivera, J. Michael McIntosh, Maren Watkins, James E. Garrett, Ki-Joon Shon, Richard B. Jacobsen, Robert M. Jones, G. Edward Cartier
-
Publication number: 20030050234Abstract: The present invention is to &mgr;-conopeptides, derivatives or pharmaceutically acceptable salts thereof. The present invention is further directed to the use of this peptide, derivatives thereof and pharmaceutically acceptable salts thereof for the treatment of disorders associated with voltage-gated sodium channels. Thus, the &mgr;-conopeptides or derivatives are useful as neuromuscular blocking agents, local anesthetic agents, analgesic agents and neuroprotective agents. The &mgr;-conopeptides are also useful for treating neuromuscular disorders. The invention is further directed to nucleic acid sequences encoding the &mgr;-conopeptides and encoding propeptides, as well as the propeptides.Type: ApplicationFiled: July 23, 2001Publication date: March 13, 2003Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventors: Baldomero M. Olivera, J. Michael McIntosh, James E. Garrett, Maren Watkins, Lourdes J. Cruz, Ki-Joon Shon, Richard B. Jacobsen, Robert M. Jones, G. Edward Cartier, Gregory S. Shen, John D. Wagstaff
-
Publication number: 20020173449Abstract: The invention relates to relatively short peptides (termed O-Superfamily conotoxins herein), about 20-40 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds.Type: ApplicationFiled: December 28, 2000Publication date: November 21, 2002Inventors: Baldomero M. Olivera, G. Edward Cartier, Maren Watkins, David R. Hillyard, J. Michael McIntosh, Richard T. Layer, Robert M. Jones
-
Publication number: 20020022715Abstract: The present invention relates to the use of &agr;-conotoxin peptides having the general formula Xaa1-Xaa2-Cys-Cys-Xaa3-Xaa4-Pro-Xaa5-Cys-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11-Xaa12-Cys (SEQ ID NO:1) for treating disorders regulated at neuronal nicotinic acetylcholine receptors. Such disorders include, but are not limited to, cardiovascular disorders, gastric motility disorders, urinary incontinence, nicotine addiction, mood disorders (such as bipolar disorder, unipolar depression, dysthymia and seasonal effective disorder) and small cell lung carcinoma, as well as the localization of small cell lung carcinoma. In this formula, Xaa1 is des-Xaa1, Tyr, mono-iodo-Tyr or di-iodo-Tyr, Xaa2 is any amino acid, Xaa3 is any amino acid, Xaa4 is any amino acid, Xaa5 is any amino acid; Xaa6 is any amino acid, Xaa7 is any amino acid, Xaa8 is any amino acid, Xaa9 is des-Xaa9 or any amino acid, Xaa10 is des-Xaa10 or any amino acid, Xaa11 is des-Xaa11 or any amino acid and Xaa2 is des-Xaa12 or any amino acid.Type: ApplicationFiled: July 3, 2001Publication date: February 21, 2002Applicant: University of Utah Research FoundationInventors: Baldomero M. Olivera, J. Michael McIntosh, Doju Yoshikami, G. Edward Cartier, Siqin Luo
-
Patent number: 6265541Abstract: The present invention relates to the use of &agr;-conotoxin peptides having the general formula Xaa1-Xaa2-Cys-Cys-Xaa3-Xaa4-Pro-Xaa5-Cys-Xaa6-Cys (SEQ ID NO: 1) for treating disorders regulated at neuronal nicotinic acetylcholine receptors. Such disorders include, but are not limited to, cardiovascular disorders, gastric motility disorders, urinary incontinence, nicotine addiction, mood disorders (such as bipolar disorder, unipolar depression, dysthymia and seasonal effective disorder) and small cell lung carcinoma, as well as the localization of small cell lung carcinoma. In this formula, Xaa1 is des-Xaa1, Tyr, mono-iodo-Tyr or di-iodo-Tyr, Xaa2 is any amino acid, Xaa3 is any amino acid, Xaa4 is any amino acid, Xaa5 is any amino acid and Xaa6 represents a peptide of 3-7 amino acids. Disulfide linkages exist between the first and third cysteines and the second and fourth cysteines. Pro may be replaced with hydroxy-Pro. The C-terminus may contain a hydroxyl or an amide group, preferably an amide group.Type: GrantFiled: December 23, 1998Date of Patent: July 24, 2001Assignee: University of Utah Research FoundationInventors: Baldomero M. Olivera, J. Michael McIntosh, Doju Yoshikami, G. Edward Cartier, Siqin Luo
-
Patent number: 5866682Abstract: This invention relates to relatively short peptides about 14-17 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogs to the naturally available peptides, and which include two cyclizing disulfide linkages. More specifically, the present invention is directed to conopeptides having the general formula: Gly-Cys-Cys-Ser-Tyr-Xaa.sub.1 -Xaa.sub.1 -Cys-Phe-Ala-Thr-Asn-Xaa.sub.2 -Xaa.sub.3 -Xaa.sub.4 -Cys (SEQ ID NO: 1), wherein Xaa.sub.1 is Pro or Hyp (trans-4-hydroxy-Pro), Xaa.sub.2 is Ser, Pro or Hyp, Xaa.sub.3 is Gly or Asp and Xaa.sub.4 is a Tyr or des- Xaa.sub.4. The disulfide bridges are between the first and third between the second fourth cysteine residues. The C-terminal end is preferably amidated.Type: GrantFiled: May 15, 1997Date of Patent: February 2, 1999Assignee: University of Utah Research FoundationInventors: J. Michael McIntosh, G. Edward Cartier, Doju Yoshikami, Siqin Luo, Baldomero M. Olivera